The Treatment of Advanced Colorectal Cancer

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 1)
Volume 1
Issue 1

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer.

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer (CRC).

Read more about the treatment of CRC andthe need for fullRASmutational analyses > >

Articles in this issue
The Identification of Molecular Subtypes of Gastric Cancer
The Identification of Molecular Subtypes of Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
New Standard of Neoadjuvant Care for Rectal Cancer Established
New Standard of Neoadjuvant Care for Rectal Cancer Established
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
The Treatment of Advanced Colorectal Cancer
The Treatment of Advanced Colorectal Cancer
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment

Tony Berberabe, MPH
March 8th 2025
Article

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

AI Writes Appeal Letters for Denied Claims...and Wins

AI Writes Appeal Letters for Denied Claims...and Wins

Todd Shryock
March 7th 2025
Article

Waystar's AI-powered AltitudeAI automates claim appeals, aiming to recover billions in denied payments and reduce healthcare administrative waste.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

FDA Accepts sBLA for Nivolumab/Ipilimumab Combo in dMMR/MSI-H CRC

FDA Accepts sBLA for Nivolumab/Ipilimumab Combo in dMMR/MSI-H CRC

Jordyn Sava
February 24th 2025
Article

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025.

Read More

Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma

Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma

Targeted Oncology Staff
February 22nd 2025
Article

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

Read More